A NOVEL HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS

被引：3
|
作者：
Wenglen, C. [1 ]
Pettersson, L. [1 ]
Arozenius, H. [1 ]
Ekstrom, G. [1 ]
机构：
[1] ANAMAR, Lund, Sweden
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.3750
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0314
引用
收藏
页码：891 / 891
页数：1
相关论文
共 50 条
  • [21] Mesenteric vasoconstrictor response to 5-hydroxytryptamine in the in situ blood autoperfused rat mesentery:: involvement of 5-HT2B and/or 5-HT2C receptor activation
    Fernández, MD
    Morán, A
    Martín, ML
    San Román, L
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 401 (02) : 221 - 227
  • [22] EFFECT OF CHRONIC ADMINISTRATION OF SELECTIVE 5-HYDROXYTRYPTAMINE AND NORADRENALINE UPTAKE INHIBITORS ON A PUTATIVE INDEX OF 5-HT2C/2B RECEPTOR FUNCTION
    KENNETT, GA
    LIGHTOWLER, S
    DEBIASI, V
    STEVENS, NC
    WOOD, MD
    TULLOCH, IF
    BLACKBURN, TP
    NEUROPHARMACOLOGY, 1994, 33 (12) : 1581 - 1588
  • [23] The Role Of 5-Ht2b Receptor Antagonism On Remodeling In Pulmonary Fibrosis
    Lofdahl, A.
    Rydell-Tormanen, K.
    Larsson-Callerfelt, A-K
    Wenglen, C.
    Westergren-Thorsson, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [24] THE 5-HT2C/2B RECEPTOR ANTAGONIST SB-200646A IS A POTENT AND SELECTIVE ANTAGONIST OF THE HUMAN 5-HT2C RECEPTOR
    WOOD, MD
    GAGER, TL
    THOMAS, DR
    NEWTON, RA
    PHIPPS, SL
    ELLIOTT, JM
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 : P155 - P155
  • [25] PGN 1091, a novel 5-HT2B receptor antagonist for the treatment of irritable bowel syndrome
    Borman, R
    Oxford, A
    Denny, S
    Sykes, A
    Samra, S
    Woodrooffe, A
    Eagle, M
    Coleman, R
    Clark, K
    GASTROENTEROLOGY, 2003, 124 (04) : A569 - A569
  • [26] 5-HT RELEASE FROM PLATELETS AND ACTIVATION OF 5-HT2B PLAY A CRUCIAL ROLE FOR DEVELOPMENT OF FIBROSIS IN SYSTEMIC SCLEROSIS
    Dees, Clara
    Akhmetshina, Alfiya
    Busch, Nicole
    Zwerina, Jochen
    Bader, Michael
    Schett, Georg
    Distler, Oliver
    Distler, Joerg H. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69
  • [27] SEROTONIN RECEPTOR 2B (5-HT2B) MODULATES CARDIOMYOCYTE PROLIFERATION BY REGULATING THE HIPPO PATHWAY
    Kwon, Dowan
    Kohar, Yulia
    Stafford, Nicholas
    Oceandy, Delvac
    HEART, 2017, 103 : A122 - A122
  • [28] Preclinical Pharmacology and Pharmacokinetics of AZD3783, a Selective 5-Hydroxytryptamine 1B Receptor Antagonist
    Zhang, Minli
    Zhou, Diansong
    Wang, Yi
    Maier, Donna L.
    Widzowski, Daniel V.
    Sobotka-Briner, Cynthia D.
    Brockel, Becky J.
    Potts, William M.
    Shenvi, Ashok B.
    Bernstein, Peter R.
    Pierson, M. Edward
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (02): : 567 - 578
  • [29] The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo
    Beattie, DT
    Smith, JAM
    Marquess, D
    Vickery, RG
    Armstrong, SR
    Pulido-Rios, T
    McCullough, JL
    Sandlund, C
    Richardson, C
    Mai, N
    Humphrey, PPA
    BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (05) : 549 - 560
  • [30] PHARMACOLOGICAL CHARACTERIZATION OF RP-62203, A NOVEL 5-HYDROXYTRYPTAMINE 5-HT2 RECEPTOR ANTAGONIST
    DOBLE, A
    GIRDLESTONE, D
    PIOT, O
    ALLAM, D
    BETSCHART, J
    BOIREAU, A
    DUPUY, A
    GUEREMY, C
    MENAGER, J
    ZUNDEL, JL
    BLANCHARD, JC
    BRITISH JOURNAL OF PHARMACOLOGY, 1992, 105 (01) : 27 - 36
12345